WO2008099907A1 - 尿排出障害治療剤 - Google Patents

尿排出障害治療剤 Download PDF

Info

Publication number
WO2008099907A1
WO2008099907A1 PCT/JP2008/052486 JP2008052486W WO2008099907A1 WO 2008099907 A1 WO2008099907 A1 WO 2008099907A1 JP 2008052486 W JP2008052486 W JP 2008052486W WO 2008099907 A1 WO2008099907 A1 WO 2008099907A1
Authority
WO
WIPO (PCT)
Prior art keywords
urinary
urinary excretion
excretion disorder
compound
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052486
Other languages
English (en)
French (fr)
Inventor
Takayuki Maruyama
Hiroki Okada
Takashi Konemura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08711316.3A priority Critical patent/EP2123273B1/en
Priority to CN200880012411.5A priority patent/CN101663034B/zh
Priority to ES08711316.3T priority patent/ES2437323T3/es
Priority to KR20097018350A priority patent/KR101492552B1/ko
Priority to CA2677769A priority patent/CA2677769C/en
Priority to JP2008558140A priority patent/JP5439817B2/ja
Priority to MX2009008606A priority patent/MX2009008606A/es
Priority to AU2008215431A priority patent/AU2008215431C1/en
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to NZ578988A priority patent/NZ578988A/en
Priority to US12/527,340 priority patent/US9181187B2/en
Priority to BRPI0807942-0A2A priority patent/BRPI0807942A2/pt
Publication of WO2008099907A1 publication Critical patent/WO2008099907A1/ja
Priority to IL200377A priority patent/IL200377A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

　本発明に係るＥＰ１アンタゴニスト、特に、一般式（Ｉ） （式中、すべての記号は明細書における記載と同じ意味を表わす。）で示される化合物、その塩もしくはそれらの溶媒和物またはそれらのプロドラッグは、尿排出障害の予防、治療および／または尿排出障害に伴う症状（尿勢低下、尿線分割、尿線途絶、排尿遅延、腹圧排尿、終末滴下等）の改善に有効である。
PCT/JP2008/052486 2007-02-16 2008-02-15 尿排出障害治療剤 Ceased WO2008099907A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2009008606A MX2009008606A (es) 2007-02-16 2008-02-15 Agente terapeutico para trastorno de excrecion urinaria.
ES08711316.3T ES2437323T3 (es) 2007-02-16 2008-02-15 Agente terapéutico para trastornos de la micción
KR20097018350A KR101492552B1 (ko) 2007-02-16 2008-02-15 요 배출 장애 치료제
CA2677769A CA2677769C (en) 2007-02-16 2008-02-15 Therapeutic agent for urinary excretion disorder
JP2008558140A JP5439817B2 (ja) 2007-02-16 2008-02-15 尿排出障害治療剤
AU2008215431A AU2008215431C1 (en) 2007-02-16 2008-02-15 Therapeutic agent for urinary excretion disorder
NZ578988A NZ578988A (en) 2007-02-16 2008-02-15 Therapeutic agent for urinary excretion disorder
EP08711316.3A EP2123273B1 (en) 2007-02-16 2008-02-15 Therapeutic agent for urinary excretion disorder
CN200880012411.5A CN101663034B (zh) 2007-02-16 2008-02-15 用于排尿障碍的治疗剂
US12/527,340 US9181187B2 (en) 2007-02-16 2008-02-15 Therapeutic agent for urinary excretion disorder
BRPI0807942-0A2A BRPI0807942A2 (pt) 2007-02-16 2008-02-15 Agente terapêutico para distúrbio de excreção urinária
IL200377A IL200377A (en) 2007-02-16 2009-08-13 Causes the prevention, treatment and / or symptom relief of dysuria and its uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-035661 2007-02-16
JP2007035661 2007-02-16

Publications (1)

Publication Number Publication Date
WO2008099907A1 true WO2008099907A1 (ja) 2008-08-21

Family

ID=39690132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052486 Ceased WO2008099907A1 (ja) 2007-02-16 2008-02-15 尿排出障害治療剤

Country Status (15)

Country Link
US (1) US9181187B2 (ja)
EP (1) EP2123273B1 (ja)
JP (1) JP5439817B2 (ja)
KR (1) KR101492552B1 (ja)
CN (1) CN101663034B (ja)
AU (1) AU2008215431C1 (ja)
BR (1) BRPI0807942A2 (ja)
CA (1) CA2677769C (ja)
ES (1) ES2437323T3 (ja)
IL (1) IL200377A (ja)
MX (1) MX2009008606A (ja)
NZ (1) NZ578988A (ja)
RU (1) RU2452479C2 (ja)
WO (1) WO2008099907A1 (ja)
ZA (1) ZA200905681B (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498097A (zh) * 2009-07-27 2012-06-13 橘生药品工业株式会社 吲哚衍生物或其可药用盐
WO2014021306A1 (ja) 2012-07-31 2014-02-06 小野薬品工業株式会社 胃食道逆流症に対する薬剤
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458650B2 (en) * 2019-10-02 2025-11-04 Aska Pharmaceutical Co., Ltd. Urination disorder-improving agent

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US530464A (en) 1894-12-04 Robert b
JPS503362B1 (ja) 1970-06-10 1975-02-04
JPS5227753B2 (ja) 1972-05-29 1977-07-22
JPS5231404B1 (ja) 1971-04-28 1977-08-15
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0160408A1 (en) 1984-04-02 1985-11-06 Merck & Co. Inc. Benzothiophenes, their production and use, and compositions containing them
EP0193822A2 (en) 1985-02-25 1986-09-10 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(thio-, sulfinyl- and sulfonyl-containing acyl)hydrazides
JPS6152146B2 (ja) 1981-03-20 1986-11-12 Ono Pharmaceutical Co
EP0218077A1 (en) 1985-08-29 1987-04-15 G.D. Searle & Co. 8-Chlorodibenz[b,f] [1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylthio-, phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4775680A (en) 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
EP0300676A2 (en) 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0480641A1 (en) 1990-10-08 1992-04-15 Zeneca Limited Tricyclic heterocycles
EP0512399A1 (en) 1991-05-03 1992-11-11 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0512400A1 (en) 1991-05-03 1992-11-11 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0534667A1 (en) 1991-09-27 1993-03-31 Zeneca Limited Tricyclic heterocycles as PGE2 antagonists
WO1993007132A1 (en) 1991-10-01 1993-04-15 G.D. Searle & Co. 10-acyl-dibenz(b,f)(1,4)-oxazepines and their thiazepines and diazepines analogues useful as prostaglandin antagonists
EP0539977A1 (en) 1991-10-31 1993-05-05 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and their use as analgesic agents and prostaglandin antagonists
WO1993013082A1 (en) 1991-12-20 1993-07-08 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists
US5281590A (en) 1991-05-03 1994-01-25 G. D. Searle & Co. 2-H and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides for the treatment of osteoporosis
US5354746A (en) 1993-06-01 1994-10-11 G. D. Searle & Co. Squaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5441950A (en) 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
WO1996003380A1 (en) 1994-07-25 1996-02-08 Zeneca Limited Aromatic amino ethers as pain relieving agents
WO1996006822A1 (en) 1994-08-31 1996-03-07 Zeneca Limited Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
WO1996011902A1 (en) 1994-10-12 1996-04-25 Zeneca Limited Pharmaceutically active substituted aromatic compounds
EP0752421A1 (en) 1995-07-07 1997-01-08 Zeneca Limited Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
WO1997000864A1 (en) 1995-06-20 1997-01-09 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
WO1997000863A1 (en) 1995-06-20 1997-01-09 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
WO1998027053A1 (en) 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient
EP0878465A2 (en) 1997-05-15 1998-11-18 Ono Pharmaceutical Co., Ltd. Benzenesulfonamide compounds
WO1999047497A2 (en) 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2000020371A1 (en) 1998-10-07 2000-04-13 Merck Frosst Canada & Co. Prostaglandin receptor ligands
WO2000069465A1 (en) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
WO2001019814A2 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2001019819A2 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2002015902A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
WO2002072098A1 (en) 2001-03-13 2002-09-19 Astrazeneca Ab Method of treatment
WO2002072564A1 (en) * 2001-03-12 2002-09-19 Ono Pharmaceutical Co., Ltd. N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2002072145A1 (en) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
WO2003043655A1 (fr) 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
WO2003074483A1 (en) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003084917A1 (en) 2002-04-08 2003-10-16 Glaxo Group Limited (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
WO2003101959A1 (en) 2002-05-31 2003-12-11 Glaxo Group Limited Pyrrole compounds for the treatment of prostaglandin mediated diseases
JP2004099493A (ja) * 2002-09-09 2004-04-02 Ono Pharmaceut Co Ltd ４−［６−［ｎ−イソブチル−ｎ−（４−メチル−２−チアゾリルスルフォニル）アミノ］インダン−５−イルオキシメチル］安息香酸の新規結晶、その製造方法およびそれを有効成分として含有する薬剤
WO2005000534A1 (ja) 2003-06-27 2005-01-06 Honda Motor Co., Ltd. 脚式移動ロボットの制御装置
WO2005010534A1 (en) 2003-07-25 2005-02-03 Pfizer Limited Ep1 receptor antagonists for the treatment of benign prostatic hypertrophy and screening method
WO2006114272A1 (en) 2005-04-26 2006-11-02 Glaxo Group Limited FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS
WO2006121097A1 (ja) 2005-05-12 2006-11-16 Astellas Pharma Inc. 二環式ヘテロ環誘導体又はその塩
WO2007072782A1 (ja) 2005-12-19 2007-06-28 Astellas Pharma Inc. カルボン酸誘導体又はその塩
WO2007113289A1 (en) 2006-04-05 2007-10-11 Glaxo Group Limited Benzofuran compounds as ep1 receptor antagonists
WO2008018544A1 (en) * 2006-08-10 2008-02-14 Astellas Pharma Inc. Sulfonamide compound or salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE69940484D1 (de) 1998-04-06 2009-04-09 Astellas Pharma Inc Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie
JP2005538139A (ja) * 2002-08-14 2005-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 男性および女性における過活動膀胱に関連する下部尿路症状の処置

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US530464A (en) 1894-12-04 Robert b
JPS503362B1 (ja) 1970-06-10 1975-02-04
JPS5231404B1 (ja) 1971-04-28 1977-08-15
JPS5227753B2 (ja) 1972-05-29 1977-07-22
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
JPS6152146B2 (ja) 1981-03-20 1986-11-12 Ono Pharmaceutical Co
EP0160408A1 (en) 1984-04-02 1985-11-06 Merck & Co. Inc. Benzothiophenes, their production and use, and compositions containing them
EP0193822A2 (en) 1985-02-25 1986-09-10 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(thio-, sulfinyl- and sulfonyl-containing acyl)hydrazides
EP0218077A1 (en) 1985-08-29 1987-04-15 G.D. Searle & Co. 8-Chlorodibenz[b,f] [1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylthio-, phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4775680A (en) 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
EP0300676A2 (en) 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0480641A1 (en) 1990-10-08 1992-04-15 Zeneca Limited Tricyclic heterocycles
WO1992019617A2 (en) 1991-05-03 1992-11-12 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5281590A (en) 1991-05-03 1994-01-25 G. D. Searle & Co. 2-H and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides for the treatment of osteoporosis
EP0512399A1 (en) 1991-05-03 1992-11-11 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0512400A1 (en) 1991-05-03 1992-11-11 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0694546A2 (en) 1991-05-03 1996-01-31 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0534667A1 (en) 1991-09-27 1993-03-31 Zeneca Limited Tricyclic heterocycles as PGE2 antagonists
WO1993007132A1 (en) 1991-10-01 1993-04-15 G.D. Searle & Co. 10-acyl-dibenz(b,f)(1,4)-oxazepines and their thiazepines and diazepines analogues useful as prostaglandin antagonists
EP0539977A1 (en) 1991-10-31 1993-05-05 G.D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and their use as analgesic agents and prostaglandin antagonists
WO1993013082A1 (en) 1991-12-20 1993-07-08 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists
US5324722A (en) 1991-12-20 1994-06-28 G. D. Searle & Co. 2-, 3-, 5-, 8-, 10- and/or 11-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5354746A (en) 1993-06-01 1994-10-11 G. D. Searle & Co. Squaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5441950A (en) 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
US5504077A (en) 1994-06-09 1996-04-02 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical composition and methods of use
WO1996003380A1 (en) 1994-07-25 1996-02-08 Zeneca Limited Aromatic amino ethers as pain relieving agents
WO1996006822A1 (en) 1994-08-31 1996-03-07 Zeneca Limited Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
WO1996011902A1 (en) 1994-10-12 1996-04-25 Zeneca Limited Pharmaceutically active substituted aromatic compounds
WO1997000864A1 (en) 1995-06-20 1997-01-09 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
WO1997000863A1 (en) 1995-06-20 1997-01-09 Zeneca Limited Aromatic compounds and pharmaceutical compositions containing them
EP0752421A1 (en) 1995-07-07 1997-01-08 Zeneca Limited Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
WO1998027053A1 (en) 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient
JP3426252B2 (ja) 1996-12-18 2003-07-14 小野薬品工業株式会社 スルフォンアミドおよびカルボアミド誘導体並びにそれらを有効成分として含有する薬剤
EP0878465A2 (en) 1997-05-15 1998-11-18 Ono Pharmaceutical Co., Ltd. Benzenesulfonamide compounds
WO1999047497A2 (en) 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2000020371A1 (en) 1998-10-07 2000-04-13 Merck Frosst Canada & Co. Prostaglandin receptor ligands
WO2000069465A1 (en) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
WO2001019819A2 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2001019814A2 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2002015902A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
WO2002072564A1 (en) * 2001-03-12 2002-09-19 Ono Pharmaceutical Co., Ltd. N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
JP3741120B2 (ja) 2001-03-12 2006-02-01 小野薬品工業株式会社 Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法
WO2002072098A1 (en) 2001-03-13 2002-09-19 Astrazeneca Ab Method of treatment
WO2002072145A1 (en) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
WO2003043655A1 (fr) 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
WO2003074483A1 (en) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003084917A1 (en) 2002-04-08 2003-10-16 Glaxo Group Limited (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
WO2003101959A1 (en) 2002-05-31 2003-12-11 Glaxo Group Limited Pyrrole compounds for the treatment of prostaglandin mediated diseases
JP2004099493A (ja) * 2002-09-09 2004-04-02 Ono Pharmaceut Co Ltd ４−［６−［ｎ−イソブチル−ｎ−（４−メチル−２−チアゾリルスルフォニル）アミノ］インダン−５−イルオキシメチル］安息香酸の新規結晶、その製造方法およびそれを有効成分として含有する薬剤
WO2005000534A1 (ja) 2003-06-27 2005-01-06 Honda Motor Co., Ltd. 脚式移動ロボットの制御装置
WO2005010534A1 (en) 2003-07-25 2005-02-03 Pfizer Limited Ep1 receptor antagonists for the treatment of benign prostatic hypertrophy and screening method
WO2006114272A1 (en) 2005-04-26 2006-11-02 Glaxo Group Limited FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS
WO2006121097A1 (ja) 2005-05-12 2006-11-16 Astellas Pharma Inc. 二環式ヘテロ環誘導体又はその塩
WO2007072782A1 (ja) 2005-12-19 2007-06-28 Astellas Pharma Inc. カルボン酸誘導体又はその塩
WO2007113289A1 (en) 2006-04-05 2007-10-11 Glaxo Group Limited Benzofuran compounds as ep1 receptor antagonists
WO2008018544A1 (en) * 2006-08-10 2008-02-14 Astellas Pharma Inc. Sulfonamide compound or salt thereof

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Iyakuhin no Kaihatsu", BUNSHI SEKKEI, vol. 7, 1990, pages 163 - 198
EUROPEAN OF UROLOGY, vol. 4, no. 5, 1978, pages 366
GENERAL PHARMACOLOGY, vol. 23, no. 5, 1992, pages 805 - 809
HALLINAN ET AL., BIOORG.MED CHEM.LETT., vol. 4, 1994, pages 509 - 514
HALLINAN ET AL., JMED.CHEM., vol. 36, 1993, pages 3293 - 3299
HALLINAN ET AL., JMEDCHEM., vol. 39, 1996, pages 609 - 613
J LIPID MEDIAT. CELL SIGNAL., vol. 12, 1995, pages 379 - 391
KAWABE K.: "Yakubutsu ni yoru Hainyo Shogai no Chiryo", GEKKAN RINSHO TO KENKYU, vol. 69, no. 9, 1992, pages 2875 - 2879, XP003021974 *
RICHARD C. LAROCK: "Comprehensive Organic Transformations : A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS INC
RUEL ET AL., BIOORG.MEDCHEM. LETT., vol. 9, pages 2699 - 2704
See also references of EP2123273A4
SYNLETT, no. 1, 2002, pages 239 - 242
TAKAMICHI HATTORI; KOSAKU YASUDA: "Shinkeiseiboukou no Shindan to Chiryo", pages: 105 - 106

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498097A (zh) * 2009-07-27 2012-06-13 橘生药品工业株式会社 吲哚衍生物或其可药用盐
WO2014021306A1 (ja) 2012-07-31 2014-02-06 小野薬品工業株式会社 胃食道逆流症に対する薬剤
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем

Also Published As

Publication number Publication date
EP2123273A4 (en) 2010-09-15
ES2437323T3 (es) 2014-01-10
NZ578988A (en) 2012-03-30
AU2008215431B2 (en) 2012-09-06
KR20090114433A (ko) 2009-11-03
CN101663034A (zh) 2010-03-03
RU2009134485A (ru) 2011-03-27
BRPI0807942A2 (pt) 2014-07-01
CA2677769A1 (en) 2008-08-21
AU2008215431C1 (en) 2013-10-17
JPWO2008099907A1 (ja) 2010-05-27
IL200377A0 (en) 2010-04-29
IL200377A (en) 2016-04-21
RU2452479C2 (ru) 2012-06-10
EP2123273B1 (en) 2013-10-23
CA2677769C (en) 2016-01-19
AU2008215431A1 (en) 2008-08-21
KR101492552B1 (ko) 2015-02-12
CN101663034B (zh) 2014-11-05
MX2009008606A (es) 2009-09-16
JP5439817B2 (ja) 2014-03-12
ZA200905681B (en) 2010-04-28
EP2123273A1 (en) 2009-11-25
US9181187B2 (en) 2015-11-10
US20100076038A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2009051244A1 (ja) 複素環化合物
WO2008137816A8 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
WO2007087442A3 (en) Substituted biaryl compounds for inflammation and immune-related uses
WO2007135527A3 (en) Benzimidazolyl compounds
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2007087441A3 (en) Substituted aromatic compounds for inflammation and immune-related uses
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2008070447A3 (en) Anti-viral compounds
WO2012083112A3 (en) C- 17 -heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2012065958A9 (en) Method of treating contrast-induced nephropathy
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2008060927A3 (en) Hepatitis c virus inhibitors
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
PL1948234T3 (pl) Kompozycje i sposoby leczenia i profilaktyki stanów fibrotycznych, zapalnych i związanych z neowaskularyzacją
WO2008063504A3 (en) Cyclohexenyl-aryl compounds for inflammation and immune-related uses
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
GB0912562D0 (en) LXR-antagonists for the prevention, reduction or inhibition of scarring
WO2008074450A3 (en) Non-peptidic renin inhibitors nitroderivatives
WO2009071947A3 (en) Potassium ion channel modulators and uses thereof
WO2008099907A1 (ja) 尿排出障害治療剤
WO2008027013A3 (en) Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009106471A3 (en) Angiotensin ii receptor blocker derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880012411.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711316

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558140

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2677769

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 578988

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008606

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200377

Country of ref document: IL

Ref document number: 2008711316

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12527340

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008215431

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097018350

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009134485

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008215431

Country of ref document: AU

Date of ref document: 20080215

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0807942

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090814